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1. Introduction 
Regulation of intracellular and extracellular potassium concentration is a fundamental 
process vital for cellular metabolism. Potassium intake, from the diet, is carefully balanced 
with excretion of potassium via the renal tract and gastrointestinal losses. Following a 
potassium load, extra-renal buffering of potassium occurs in peripheral tissues prior to its 
excretion. Thus potassium regulation is achieved by both short term and long term 
mechanisms. It has become clear that a series of potassium ion channels and transporter 
proteins have physiologically important roles throughout the length of the nephron. Our 
knowledge of normal physiological mechanisms has been increased by studying molecular 
defects responsible for variety of disorders associated with potassium transport. Studying 
renal tubular epithelial cell proteins and their regulation has improved the understanding of 
inherited tubular disorders which may cause hypokalemia.  
Here, we review the normal renal tubular handling of potassium and discuss the molecular 
basis of clinical syndromes associated with hypokalemic alkalosis and hypokalemic forms of 
hypertension.  
2. Renal tubular handling of potassium 
2.1 Glomerular filtration and proximal tubule 
Glomerular filtration produces >160 L of filtrate per day in a healthy adult, and 99% of this 
volume and majority of filtered solutes are reabsorbed along the nephron. The filtrate is 
identical to that of plasma with respect to water and solutes of low molecular weight, such 
as glucose, chloride, sodium, phosphate, urea, uric acid, creatinine and potassium. 
The proximal convoluted tubule is responsible for reabsorption of glucose, amino acids, 
phosphate, sodium and low-molecular weight proteins. Around 65% of filtered sodium is 
reabsorbed in the proximal tubule. Potassium reabsorption is closely coupled to sodium 
transport (driven passively by the electrical gradient) and around 75% of filtered potassium 
is reabsorbed by the proximal convoluted tubule. The proximal straight tubule may secrete 
some potassium into the urine, and this secretion can be upregulated significantly in 
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patients with chronic kidney disease. Generalized defects in proximal tubule handling of 
solutes result in Fanconi syndrome syndrome. Specific proximal tubular handling defects 
leading to hypokalemia include proximal renal tubular acidosis, and have been recently 
reviewed elsewhere (Fry &Karet, 2007).  
2.2 Potassium movement in the thin loop of Henle 
Potassium may be secreted in the thin descending loops of Henle that penetrate the inner 
medulla, whilst the thin ascending loop is permeable to sodium and potassium and allows 
some uptake. 
The thin ascending limbs of the loops of Henle (among other nephron segments) express the 
CLC-KA chloride channel, with its subunit Barttin. Polymorphisms in CLCNKA have 
recently been associated with a hyperreninemic hyperaldosteronism, implicating a key role 
for this channel in regulating renal salt handling and determining a set point for renin and 
angiotensin levels (Cappola, et al., 2011). 
2.3 Potassium movement in thick ascending loop of Henle  
In this part of nephron, ~25% of filtered sodium is reabsorbed together with ~15% of the 
filtered potassium. Transcellular sodium and potassium transport is achieved by the 
Na+K+2Cl- cotransporter (NKCC2) in the apical membrane, driven by the basolateral 
Na+K+ATPase pump. Alternative names for NKCC2 include the bumetanide sensitive co-
transporter, (BSC). NKCC2 is exclusively expressed in kidney tissue and is encoded by 
SLC12A1 gene (Simon, et al., 1996a). The NKCC2 transporter may also transport ammonium 
ions, which compete with potassium ions. 
 Potassium entering the cell via NKCC2 is recycled back into tubule lumen via the apical 
membrane channel, ROMK1 (Simon, et al., 1996b), generating a lumen positive potential 
driving paracellular resorption of calcium and magnesium. Tight junction proteins, such as 
paracellin 1, mediate this divalent cation transport. ROMK1, also known as a KCNJ, is an 
ATPase sensitive potassium channel. Functional coupling of ROMK1 with NKCC2 is 
essential for NaCl reabsorption. Chloride exits the basolateral membrane of the TAL via the 
CLC chloride channel, CLC-KB, which is co-expressed with the subunit Barttin. 
2.4 The distal convoluted tubule  
The distal convoluted tubule is responsible for ~8% of filtered sodium reabsorption. This is 
achieved via an apical Na+Cl- cotransporter (NCCT, alias the thiazide sensitive sodium 
chloride transporter). This transporter is regulated by a group of serine-threonine protein 
kinases, incluidng WNK4. In healthy individuals, WNK4 inhibits NCCT function by 
reducing its expression on the membrane.  
Recent data has suggested that potassium channels control DCT function. An apically 
expressed potassium channel Kv1.1 is postulated to stabilise the luminal membrane 
potential in this nephron segment (Glaudemans, et al., 2009). and facilitates effective 
magnesium transport via the apical TRPM6 magnesium channel. At the basolateral 
membrane of the DCT a potassium channel Kir4.1 is thought to allow potassium recycling, 
allowing maintenance of the basolateral Na+K+ATPase activity, the driving force for NaCl 
reabsorption via NCCT in this nephron segment (Bockenhauer, et al., 2009, Scholl, et  
al., 2009). 
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2.5 The collecting ducts  
The connecting tubules, initial collecting tubule and the cortical collecting duct, are major 
sites of regulated potassium secretion. Indeed, potassium secretion in these nephron 
segments may be upregulated to exceed the filtered load of potassium. In addition, if 
potassium reabsorption is required, this part of the nephron and regions of the medullary 
collecting duct may reabsorb potassium. In the cortical collecting duct two important cell 
types mediate potassium transport: principal cells and intercalated cells. 
In principal cells, sodium entry occurs via selective sodium channels (ENaCs), located on 
apical membrane. Potassium secretion in these cells occurs by a transcellular movement of 
potassium, mediated by a basolateral Na+K+ATPase pump and apical ROMK potassium 
channels. Potassium secretion is directly linked to sodium entry via ENaC. 
The distribution of ENaC channels within the apical membrane is regulated by effects of 
aldosterone on the mineralocorticoid receptor. The ENaC channel has three subunits: alpha, 
beta and gamma encoded by genes SCNN1A, SCNN1B and SCNN1C. Alpha-intercalated 
cells in the cortical collecting duct mediate potassium reabsorption. An apical H+K+ATPase 
pump allows potassium reabsorption coupled to proton excretion, whilst an apical proton 
pump transports hydrogen ions into the lumen. In states of potassium depletion, there is 
upregulation of the apical H+K+ATPase pump in alpha intercalated cells. 
3. When hypokalemia may be the presentation of an inherited tubulopathy? 
Physiological serum potassium levels are usually tightly maintained between 3.5-5.0 mmol/L. 
Hypokalemia represents a deviation from this regulation and may be defined as mild, 
moderate or severe. Mild hypokalemia (Serum K+ 3.0-3.5 mmol/L) is usually asymptomatic 
whilst moderate hypokalemia (Serum K+ 2.5-3.0 mmol/L) may present with muscle weakness, 
myalgia, arrhythmias, cramps and constipation. With severe hypokalemia, (K+ <2mmol/L), 
hyporeflexia, flaccid paralysis and occasionally rhabdomyolysis occur. There are many causes 
of hypokalemia to be considered before a renal tubulopathy is suspected. These can be divided 
into an assessment of potassium intake, potassium distribution within tissues and potassium 
excretion (see Table 1). In order to assess this, a careful history including history of drugs and 
over the counter medications, and the presence of Gastrointestinal (GI) disturbance (vomiting 
or diarrhoea) should be sought. Clinical examination (including blood pressure (BP) and 
orthostatic changes in BP)) is also necessary. This, combined with serum and urine 
biochemistry (including osmolality) will help to assess the causes of hypokalemia. 
Occasionally, a high WBC count may be associated with a spurious low serum potassium 
level. Pseudohypokalemia has recently been reported in 2 patients with hereditary 
spherocytosis secondary to AE1 mutations (Norgett, et al., 2011). 
Potassium is present in a wide variety of foods (citrus fruits, vegetables, meat). Therefore, 
examples of inadequate intake are limited to anorexia, bulimia, alcoholism and starvation. 
Certain factors may affect the distribution of potassium from extracellular to intracellular 
compartments, leading to hypokalemia. Endogenous or administered insulin, 
catecholamines, beta-agonists and metabolic alkalosis will all promote cellular uptake of 
potassium. Excretion of potassium may be grouped into extra renal loss and renal loss. Extra 
renal loss of potassium is mainly via the gastrointestinal tract (GI) and may occur with 
diarrhoea, GI fistulas, and laxative abuse. Renal loss of potassium may be associated with a 
variety of acquired and inherited tubular disorders and drugs. Amphotericin B, 
aminoglycosides and cisplatin all increase renal potassium losses. Many diuretics, apart 
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from potassium-sparing ones, cause increased urinary losses of potassium. Magnesium 
depletion may also lead to renal potassium wasting. A 24 h urine collection can be used to 
assess renal potassium excretion in a hypokalemia patient. This should be < 15 mmol/24 h if 
there is extra renal potassium wasting. In a similar way, a spot urine for a 
potassium/creatinine ratio should be less than 1 in the presence of extra renal potassium 
wasting. Calculations of transtubular potassium gradient will give similar information. 
Urinary chloride will also be low in cases of significant GI volume losses (vomiting, 
diarrhoea, laxative abuse). If renal K wasting is suspected and confirmed then further 
thought regarding the blood pressure and acid base status of the patient aids the diagnosis 
of hypokalemia. 
 
Extra-renal Hypokalemia 
 
Spurious Extra-renal Loss Redistribution 
   
High WBC count Diarrhoea Acid-base disturbance 
Hereditary 
spherocytosis 
GI fistulas Insulin excess 
 Laxative abuse Beta-adrenergic agonists 
 
Dietary 
insufficiency 
Drugs / toxins e.g. Barium, 
catecholamines 
 Cutaneous losses 
Hypokalemic periodic  
paralysis (familial and 
thyrotoxic) 
Table 1. Causes of extra-renal hypokalemia 
Reasons to suspect an inherited tubulopathy may include evidence for a persistent 
electrolyte disturbance, the presence of renal impairment, nephrocalcinosis and renal stone 
formation (Sayer &Pearce, 2001). A detailed and extensive family history is necessary. In 
paediatric cases, faltering growth, abnormal growth patterns, developmental delay and 
deafness may all be clues to an inherited tubulopathy. Neonates may present with a salt-
wasting crisis and are particularly sensitive to severe hypovolemia and electrolyte 
disturbance due to immature tubular physiology and low-salt intakes in standard feeds. 
With nephron maturation, the propensity to present with salt-wasting crises decreases. 
Individual tubular diseases can be differentiated by their serum and urine biochemical 
profiles (discussed below). Hypokalemia may be the only presenting feature of a 
tubulopathy and it is important to follow the diagnostic ‘lead’ to differentiate the many 
causes. Nephrocalcinosis should be thoroughly investigated and differential diagnosis such 
as hyperparathyroidism, vitamin D intoxication and sarcoidosis first excluded. Renal 
tubular disorders associated with nephrocalcinosis include Bartter’s syndrome, Dent’s 
disease, hypomagnesemic hypercalciuric nephrolithiasis, idiopathic hypercalciuria and 
distal renal tubular acidosis.  
Renal tubulopathies are best investigated by urine pH and 24-hour urine collection  
for potassium, calcium, magnesium, citrate and phosphate along with serum biochemistry. 
Nevertheless, renal tubulopathies are rare and they should be considered only after  
www.intechopen.com
 
Renal Potassium Handling and Associated Inherited Tubulopathies Leading to Hypokalemia 
 
93 
careful drug and dietary histories are taken, together with urine electrolytes and serum 
biochemistry.  
4. Inherited tubulopathies leading to hypokalemic alkalosis 
4.1 Bartter’s syndrome 
Bartter’s syndrome is an autosomal recessive renal disorder described by Bartter et al. in 
1962 (Bartter, et al., 1962). It has estimated incidence of 1.2 per million (Rudin, 1988). 
Impaired salt (sodium chloride) reabsorption in the thick ascending loop of Henle (TAL) 
leads to renal salt wasting and a hypokalemic metabolic alkalosis. The majority of cases 
present in the early neonatal period with salt-losing crises. An antenatal diagnosis can also 
be suspected if a pregnancy is complicated by polyhydramnios or premature birth (Sieck 
&Ohlsson, 1984). Bartter’s syndrome is also associated with short stature, growth 
retardation in infancy, muscle weakness, polyuria and polydipsia. Some children have 
characteristic facies that are triangular-shaped with a prominent forehead, large eyes, 
protruding ears and a drooping mouth. Blood pressure is normal. Bartter’s syndrome 
should be suspected in patient presenting with the above symptoms and signs and the 
following laboratory findings: hypokalemic alkalosis, high urinary chloride and urinary 
potassium levels and normal or raised urinary calcium level. Serum magnesium levels are 
typically normal or mildly low. 
The biochemical abnormalities are a consequence of renal salt wasting in the TAL. This 
stimulates the renin-angiotensin II-aldosterone system (RAAS) and causes hyperplasia of 
juxtaglomerular apparatus, a feature originally noted by Bartter (Bartter, et al., 1962). Raised 
RAAS increases sodium reabsorption in the distal nephron (via ENaC) in exchange for K+ 
and H+, which leads to hypokalemic alkalosis. Increases in prostaglandin E2 synthesis 
aggravate the salt wasting by its effect on ROMK1 and NKCC2. Despite raised RAAS, 
leading to hyperreninemia and hyperaldosteronism, patients with Bartter’s syndrome 
remain normotensive. The various phenotypes of Bartter’s syndrome are now more simply 
classified by their underlying genetic mutation. 
Antenatal Bartter’s syndrome (Type 1) is caused by homozygous or compound 
heterozygous mutation in the SLC12A1 gene, encoding NKCC2 (Simon, et al., 1996a). 
NKCC2 is kidney specific, electroneutral transporter protein, located at the apical membrane 
of the TAL (Simon, et al., 1996a). 
Type 1 is a severe form of Bartter’s syndrome which may present in utero with marked 
polyhydramnios and premature birth. Amniocentesis shows high chloride (and aldosterone) 
levels. Analysis of a pregnant mother’s urine may also suggest the diagnosis, demonstrating 
low Na+, Cl- and Ca2+ (Matsushita, et al., 1999). A definitive diagnosis may be made using 
mutational analysis of DNA from amniocytes (Konrad, et al., 1999). 
Prenatal diagnosis is important as indomethacin may be a useful treatment for 
polyhydramnios (Smith et al., 1990). and early neonatal treatment may be life saving. 
Neonates typically present with severe salt-wasting crises, hypokalemic alkalosis, 
vomiting and diarrhoea. The latter two symptoms are due to renal activation of 
prostaglandin synthesis, as a consequence of hypokalemia. A feature that distinguishes 
this type from others is marked hypercalciuria, which causes nephrocalcinosis and 
osteopenia in infancy. Treatment is with potassium supplements, often combined with 
potassium-sparing diuretics (such as spironolactone and amiloride) and inhibitors of 
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prostaglandin-stimulated renin release (such as indomethacin and specific cyclo-
oxygensae (COX-2) inhibitors). 
Antenatal Bartter’s syndrome (Type 2) is clinically indistinguishable from Type 1. It is 
caused by loss-of-function mutations in the KCNJ1 gene (alias ROMK1) encoding the ATP-
sensitive potassium channel ROMK1, also located apically in the TAL (Simon, et al., 1996b). 
ROMK1 allows potassium recycling from the TAL cells back to the luminal filtrate, and is 
electrogenic driving paracellular reabsorption of sodium, calcium and magnesium. ROMK1 
is a regulator of the NKCC2 co-transporter and functional coupling of ROMK1 with NKCC2 
is essential for effective NaCl reabsorption. Therefore, functional defects in the ROMK1 
protein severely disrupt electrogenic chloride reabsorption in TAL, resulting in a similar 
antenatal phenotype, although the hypokalemia may be less severe (Kurtz, 1998). The 
treatment of Bartter’s syndrome Type 2 is the same as for Bartter’s syndrome Type 1. 
Classic Bartter’s syndrome (Type 3) is caused by mutations in CLCNKB encoding the CLC 
chloride channel member CLC-KB. This channel protein is located on the basolateral 
membrane of TAL cells, where it co-localizes with Barttin. The presentation of Type 3 / 
Classic Bartter’s syndrome tends to be with weakness and hypovolemia during early 
childhood, with a milder defect of urinary concentrating ability and normal urinary calcium 
levels. Hence, nephrocalcinosis or nephrolithiasis is rarely a feature. Severe and chronic 
hypokalemia may lead to medullary cyst formation (Ariceta &Rodriguez-Soriano, 2006). 
Hyperuricemia may occur due to volume contraction. Renal function is usually preserved 
initially but may decrease as a result of chronic hypokalemia and tubulointerstitial damage. 
The primary defect alters chloride reabsorption, with defective basolateral exit of chloride 
via CLC-KB in the TAL. Clinical features in Type 3 Bartter’s syndrome include short stature 
and salt wasting. However, CLCNKB mutations may present with variable phenotype, 
ranging from neonatal salt losing crises to asymptomatic patients detected in adulthood by 
routine electrolyte testing (Konrad, et al., 2000). A milder phenotype may be confused with 
Gitelman’s syndrome. Indeed, some patients with CLCKNB mutations have profound 
hypomagnesaemia and hypocalciuria, closely mimicking Gitelman’s syndrome (Jeck, et al., 
2000,Konrad, et al., 2000).  
Bartter’s syndrome Type 4A is a form of infantile Bartter’s syndrome caused by a mutation 
in the gene BSND encoding Barttin (Estevez, et al., 2001). Barttin is two-transmembrane 
protein and an essential subunit of the CLC chloride channels CLC-KB and CLC-KA. Barttin 
modulates both membrane insertion and function of both CLC-KA and CLC-KB (Scholl, et 
al., 2006,Waldegger, et al., 2002). In the kidney Barttin is expressed in the thin limb and the 
TAL of Henle. This type of Bartter’s syndrome is associated with congenital sensorineural 
deafness (termed BSND) which may explained by the localisation of Barttin protein as a 
subunit for CLC-KA in inner ear cells. Again, the phenotype can be severe neonatal salt 
wasting or a more mild adult presentation (Miyamura, et al., 2003).  
Type 4B Bartter’s syndrome is associated with simultaneous mutations in both chloride 
channel genes, CLCNKA and CLCNKB resulting in sensorineural deafness and renal salt 
wasting. This form of Bartter’s syndrome is rare but should be considered when BSND 
mutations are not detected. Children from consanguineous parents with homozygous 
mutations in both genes (Schlingmann, et al., 2004) and non consanguineous parents with 
digenic compound heterozygous mutations have been described (Nozu, et al., 2008).  
Bartter’s syndrome Type 5 is better known as autosomal dominant hypocalcaemia with 
Bartter’syndrome. Mutations in the CASR gene encoding the Calcium-sensing receptor can 
occasionally be associated with a Bartter’s like phenotype (Vargas-Poussou, et al., 
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2002,Watanabe, et al., 2002). The mechanism leading to this phenotype is thought to be 
constitutive activation of the mutant CASR, located on the basolateral membrane of the 
TAL, by normal serum calcium levels, leading to a secondary inhibition of sodium chloride 
transport in the TAL, thus mimicking Bartter’s syndrome. Of note, the degree of metabolic 
alkalosis in these patients was mild (Sayer &Pearce, 2003). 
4.2 Pseudo Bartter’s syndrome 
Pseudo antenatal Bartter’s syndrome has been reported in a preterm child with cyanotic 
heart disease treated with high dose prostaglandins (Langhendries, et al., 1989). The 
biochemical phenotype of Bartter’s may also be mimicked by loop diuretic abuse. 
Hypokalemic metabolic alkalosis may also be seen in patients with cystic fibrosis, bulimia 
and laxative abuse. In such cases, urinary chloride levels are low, given the salt wasting is 
not secondary to a tubular defect. 
4.3 Gitelman’s syndrome 
Gitelman’s syndrome refers to an autosomal recessive congenital condition, which is 
characterized by a hypokalemic alkalosis with hypocalciuria and often hypomagnesaemia 
(Gitelman, et al., 1966). Gitelman’s syndrome has incidence of 1:40,000, which makes it one 
of the commonest inherited tubulopathies. The electrolyte disturbance mimics that of 
chronic thiazide diuretic use. Patients with this syndrome have genetic defect in the 
SLC12A3 gene encoding the thiazide-sensitive sodium-chloride cotransporter (NCCT) 
(Simon, et al., 1996a). This cotransporter is located in the apical membrane of distal 
convoluted tubular (DCT) cells. Defects in NCCT result in reduced sodium reabsorption in 
the DCT, leading to increased delivery of sodium to the CCD. This leads to increased 
absorption of sodium via ENaC, coupled with K excretion, leading to hypokalemia. 
Subsequent stimulation of K reabsorption via H+K+ATPase in intercalated cells results in a 
metabolic alkalosis. Within the DCT, transcellular absorption of magnesium (via the apical 
magnesium channel TRPM6 and a putative basolateral Na+/Mg2+ exchanger) is  
also reduced. The exact mechanism of hypocalciuria has been the subject of speculation for 
some time. Evidence from studying thiazide treatment in murine models now suggests that 
as result of volume contraction enhanced proximal tubular sodium reabsorption occurs,  
and with it, an increase in proximal tubular paracellular absorption of calcium (Nijenhuis,  
et al., 2005).  
Gitelman’s syndrome is often asymptomatic into adult life, presenting with weakness, 
paraesthesia, fatigue and tetany. Salt craving may be a feature. Typically the patients are 
normotensive and may have polyarthritis and chondrocalcinosis secondary to severe and 
longstanding hypomagnesaemia (Cobeta-Garcia, et al., 1998). Clinical diagnostic features 
for Gitelman’s syndrome include a low urinary calcium:creatinine ratio (typically <0.2), 
low serum magnesium (<0.65 mmol/L) and a hypokalemic metabolic alkalosis, once 
thiazide use is ruled out. Surreptitious ingestion of thiazide may be ruled out by screening 
the urine. Cisplastin nephrotoxicity may resemble Gitelman’s syndrome as may some of 
the magnesium wasting tubulopathies (Knoers et al., 2003) discussed below. Treatment is 
with lifelong potassium and magnesium supplements and diet rich in sodium and 
potassium. Amiloride and spironolactone may also be useful treatments to ensure 
maintained serum potassium levels. Occasionally, a severe childhood onset phenotype 
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may occur, mimicking Bartter’s syndrome in terms of severity. Early replacement of 
electrolytes is important and in common with Bartter’s syndrome, NSAIDs have been 
used to good effect to promote growth in these children (Liaw, et al., 1999). Patients with 
Gitelman’s syndrome have very good long term prognosis, however sudden cardiac 
deaths associated with prolonged QT intervals and cardiac arrhythmias have been 
reported (Cortesi, et al., 2010). In keeping with this less than benign phenotype, 
Gitelman’s patients may have severe symptoms which are debilitating. For example, 
weakness, tetany and cramps are often so severe that emergency admissions to hospitals 
are required for intravenous potassium and magnesium replacement. Indeed, following 
quality of life questionnaires, Gitelman’s patients’ scores were comparable to patients 
with congestive heart failure (Cruz, et al., 2001). As discussed previously, mutations in 
CLCNKB encoding the basolateral chloride channel can also cause a Gitelman’s 
phenotype. CLC-KB is expressed in the DCT as well as the TAL, accounting for this 
phenotypic overlap. Indeed, patients within the same family with identical CLCNKB 
mutation may present with a spectrum of phenotypes including both Bartter’s and 
Gitelman’s syndrome (Zelikovic, et al., 2003). In a recent large cohort of 448 Gitelman’s 
patients, CLCNKB mutations accounted for just 3% of cases (Vargas-Poussou, et al., 2011). 
4.4 “Pseudo” Gitelman’s syndrome and reverse phenotypes 
The molecular basis for the syndrome of autosomal dominant hypomagnesemia has recently 
been made (Glaudemans, et al., 2009). This syndrome presents in childhood with recurrent 
muscle cramps, tetanic episodes, tremor, and muscle weakness. Patients have low serum 
Mg2+ levels, while serum K+ and Ca2+ levels and urinary Ca2+ excretion are not affected. This 
condition is therefore biochemically different from both Gitelman’s syndrome and other 
forms of inherited hypomagnesemia. Mutations were identified in the KCNA1 gene, 
encoding the Kv1.1 potassium channel, expressed in the apical membrane of the DCT and 
connecting tubule (Glaudemans, et al., 2009). This potassium channel is thought to work to 
stabilize the apical membrane, in the context of TRPM6 mediated magnesium reabsportion 
in these nephron segments. Loss of function mutations leads to a depolarisation of the 
membrane and defective magnesium reabsorption, resulting in hypermagnesuria and 
hypomagnesemia. 
In contrast to Gitelman’s, the biochemical phenotype of patients with familial 
hypomagnesemia with hypercalciuria and nephrocalcinosis secondary to mutations in the 
genes encoding claudin 16 and claudin 19 includes hypercalciuria rather than hypocalciuria.  
Isolated dominant hypomagnesemia caused by mutations in FXYD2 leads to hypocalciuria, 
and can resemble Gitelman’s syndrome. Patient may be relatively symptom free as 
magneseium levels are mildly low, and may also have chondrocalcinosis (Geven, et al., 
1987,Meij, et al., 2000). Recently a complex syndrome including epilepsy, ataxia, 
sensorineural deafness and a tubulopathy resulting in Gitelman’s like biochemical 
derangement has been described (Bockenhauer, et al., 2009, Scholl, et al., 2009). The 
syndrome has been named both EAST syndrome (Bockenhauer, et al., 2009) and SeSAME 
syndrome (Scholl, et al., 2009). The biochemical defects are hypokalemia, metabolic 
alkalosis, hypomagnesemia and hypocalciuria. Mutations have been identified in the 
KCJN10 gene encoding the renal Kir4.1 potassium channel, located on the basolateral 
membrane of the DCT. Loss of function mutations therefore disrupt DCT tubular handling 
www.intechopen.com
 
Renal Potassium Handling and Associated Inherited Tubulopathies Leading to Hypokalemia 
 
97 
of salts in a similar manner to NCCT defects, leading to secondary activation of the renin-
angiotensin-aldosterone axis. 
Recent molecular genetic studies have identified the basis of Gordon syndrome, also known 
as pseudohypoaldosteronism type II or chloride shunt syndrome, an autosomal dominant 
form of hypertension. It is noteworthy and mentioned here given that the diagnostic 
features resemble a mirror image of Gitelman’s syndrome. This includes hyperkalemia, 
hypertension and hyperchloraemic metabolic acidosis. It can present in early neonatal 
period with hyperkalemic acidosis or later in life with hypertension. Additional clinical 
features include short stature, muscle weakness, intellectual impairment and dental 
abnormalities. Laboratory findings include low fractional excretion of sodium, low renin 
and aldosterone levels and normal renal function. This syndrome is caused by mutations in 
the gene encoding WNK4 (Lalioti, et al., 2006), which is a member of serine-threonine 
protein kinases. In humans, WNK4 is present exclusively in kidney. WNK4 acts as an 
inhibitor of thiazide-sensitive sodium-chloride co-transporter (NCCT). Mutations in WNK4 
relieve this inhibition causing excess sodium retention and subsequent hypertension. 
Hyperkalemia is explained by inhibition of potassium ROMK channels. Treatment of 
Gordon syndrome is with low potassium diet and use of thiazide diuretics. Sodium loading 
should be avoided as it may worsen hypertension. 
4.5 Liddle’s syndrome 
Liddle’s syndrome, also called pseudoaldosteronism, is an autosomal dominant disorder 
which is characterized by early onset severe hypertension, suppressed renin and 
aldosterone levels and hypokalaemic metabolic alkalosis (Liddle, et al., 1963). This 
syndrome is a familial renal disorder simulating primary aldosteronism but with 
negligible aldosterone secretion and is caused by up regulation of epithelial Na channel 
(ENaC) located in the collecting duct. Up regulation leaves the ENaC in ‘open’ state which 
enhances sodium reabsorption and causes hypertension. ENaC is a heterotrimeric protein, 
its three subunits named alpha, beta and gamma. Mutations in the beta and gamma 
subunits can cause constitutive channel opening (Hansson, et al., 1995a, Hansson, et al., 
1995b). The beta and gamma subunits of ENaC are encoded by SCNN1B and SCNN1G 
genes, respectively. A key regulator of ENaC is NEDD4L, which is able to ubiquitinate 
ENaC leading to its removal from the luminal cell membrane in the renal collecting ducts. 
It has been postulated that loss of function defects in NEDD4L or alternative splicing of 
NEDD4L may also lead to hypertension (Dunn, et al., 2002). Patients with Liddle’s 
syndrome are often asymptomatic and they are usually investigated after incidental 
finding of hypertension. Affected children may have symptomatic polyuria and 
polydipsia and faltering growth. A strong family history of premature stroke may prompt 
investigations. Liddle’s syndrome should be suspected in a young person with high blood 
pressure, a family history of hypertension and low serum potassium together with a 
metabolic alkalosis. However, Liddle’s syndrome may mimic essential hypertension as 
hypokalemia may not always be present (Rossi, et al., 2011). Indeed, genetic variants in 
ENaC genes may be found in patients with presumed essential hypertension (Hannila-
Handelberg, et al., 2005). In Liddle’s syndrome, there is a high variability of penetration 
which appears to be dependent on environmental factors such as dietary salt intake. 
Because serum and urine aldosterone levels are low, differential diagnosis should include 
certain forms of congenital adrenal hyperplasia, syndrome of apparent mineralocorticoid 
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excess, chronic liquorice ingestion and carbenoxolone therapy. Treatment of Liddle’s 
syndrome consists of sodium restriction and potassium-sparing diuretics, like amiloride 
and triamterene, which directly inhibit the ENaC. There is no benefit of using 
mineralocorticoid antagonists, such as spironololactone, as in this syndrome the up 
regulation of ENaC is not mediated by aldosterone. 
4.6 Syndrome of Apparent Mineralocorticoid Excess (AME) 
This autosomal recessive syndrome is characterised by hypertension, hypokalemia, 
metabolic alkalosis, with suppressed renin and aldosterone levels. Hypercalciuria and 
nephrocalcinosis may occur. Typically, an affected child will have polyuria and 
polydipsia, low birth weight and faltering growth. The molecular basis for this syndrome 
is secondary to mutations in the HSD11B2 gene encoding the enzyme 11-beta-
hydroxysteroid dehydrogenase 2 (Wilson, et al., 1995). This enzyme normally inactivates 
cortisol to cortisone, preventing overstimulation of the mineralocorticoid receptor (MR). 
Mutations lead to an excess of cortisol which is able to have a mineralocorticoid–like 
affect and stimulate sodium retention, volume expansion and renin and aldosterone 
suppression. 
This syndrome may be mimicked by licorice ingestion (Walker &Edwards, 1994). Licorice 
contains glycyrrhizinic acid, which inhibits 11-beta-HSD2. Carbenoxolone also inhibits this 
enzyme. The treatment of choice for AME is a mineralocorticoid receptor blocker such as 
spironolactone or epleronone.  
4.7 Activating mutations of the mineralocorticoid receptor 
In a family with familial hypertension, hypokalemia and suppressed aldosterone levels, 
heterozygous mutations were identified in the NR3C2 gene encoding the 
mineralocorticoid receptor (MR), resulting in a gain of function (Geller, et al., 2000). 
Additionally, the specificity of the MR was altered such that progesterone was able to 
bind to it and activate it. Thus pregnant females in this family presented with severe 
hypertension.  
4.8 Glucocorticoid remediable hypertension 
Glucocorticoid remediable hypertension (also known as familial hyperaldosteronism type I) 
is characterised by autosomal dominant hypertension, low plasma renin levels, normal 
plasma aldosterone levels and hypokalemia (McMahon &Dluhy, 2004). The age of onset of 
hypertension is usually in teenage years, but may be in adulthood. Hypertension is typically 
refractory to treatment. The molecular basis for disease is secondary to a chimeric gene, 
involving CYP11B1, encoding 11-beta-hydroxylase and CYP11B2, encoding aldosterone 
synthase. The chimeric gene results in aldosterone synthesis under the regulatory control of 
ACTH, resulting in hyperaldosteronism (Lifton, et al., 1992). Thus, the causative mutation 
affects the cortical collecting duct indirectly, and therefore this is not a “tubulopathy”. 
Traditionally, diagnosis has been made by a dexamathasone suppression test, which results 
in reduced plasma aldosterone levels. A specific urinary profile of 18 oxotetrahydrocortisol 
and 18 hydrocortisol may be sought, but molecular genetic testing also allows a definitive 
diagnosis. Treatment with glucocorticoids (using shorter acting agents prednisone  
or hydrocortisone) is often effective, but additional antihypertensives may be needed  
as adjuncts. 
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5. Conclusions 
The ability to provide a definitive molecular genetic diagnosis to a patient with an 
inherited tubulopathy allows a confidence in the diagnosis, despite phenotypic 
variabilities (which may be intrafamilial). A molecular genetic diagnosis also allows the 
targeted pharmacology to be employed to achieve normalization / improvement in 
symptoms, serum biochemistry and blood pressure. The discovery of renal tubular 
transporters and channels has allowed significant gains in our understanding of this 
group of renal diseases, with families with inherited tubulopathies providing the ultimate 
“animal model”. Although perhaps uncommon, the discovery of the molecular players of 
salt and water handling within the nephron has allowed applications to be made to 
sufferers of “essential hypertension”. 
It is certainly true that a patient with hypokalemia / metabolic alkalosis, no matter how 
mild, warrants further evaluation to determine the underlying cause.  
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